Here is something nobody talks about: Most therapeutic nanoparticles are being forced through the wrong regulatory pathway. BIOS research reveals that among FDA-approved nanoparticle therapeutics, 29% are polymeric, 22% liposomal, 21% lipid-based—but nearly all went through biologics/drug approval requiring full Phase I-III trials.
Wait. Why?
The same nanoparticle delivering a drug could be classified as a medical device if the primary mechanism is physical delivery rather than chemical action. Medical devices focus on safety and performance per MDR Annex I requirements. Drugs require extensive Phase 1-4 trials proving safety, efficacy, and quality—often taking 10+ years.
Device pathway: CE marking via notified bodies, 510(k) clearance for substantial equivalence. Drug pathway: $100M+ clinical trials, multi-year regulatory review, extensive pharmacokinetic data.
The strategic insight: The label determines the pathway. Same molecule, same delivery system, completely different timeline to patients.
Notice what nobody questions: Why is a liposome delivering doxorubicin automatically a "drug" when the innovation is the delivery system, not the active ingredient? The nanoparticle itself is doing the therapeutic work—targeting, controlled release, reduced toxicity. That sounds like device functionality.
BIOS data shows regulatory complexity is killing innovation: "Considerations for Drug Products that Contain Nanomaterials" creates additional FDA requirements on top of standard drug approval. Meanwhile, device regulations emphasize equivalence and performance—exactly what m